Survodutide

Survodutide is a novel dual receptor agonist that selectively targets and activates both the glucagon receptor and the glucagon-like peptide 1 (GLP-1) receptor, a unique mechanism of action that combines the complementary metabolic benefits of both receptor pathways for the management of complex metabolic disorders. In a pivotal Phase II clinical trial enrolling patients with comorbid type 2 diabetes and obesity, Survodutide demonstrated robust and clinically relevant blood glucose-lowering efficacy, effectively regulating glycemic control in this patient population; concurrently, the agent was associated with meaningful, clinically measurable weight loss outcomes, a key therapeutic benefit for individuals living with both metabolic conditions⁽¹⁾. Beyond its promising results in type 2 diabetes and obesity, Survodutide is also the subject of ongoing active clinical research and development, with dedicated investigations underway to evaluate its safety and efficacy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver condition closely linked to systemic metabolic dysregulation.